Evidence map›Paper›PMID 26309780›Full record

ReviewBioResearch open access2015

Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells.

Anastasia Yu Efimenko, Tatiana N Kochegura, Zhanna A Akopyan, Yelena V Parfyonova

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioResearch open access, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Aging and obesity prime the methylome and transcriptome of adipose stem cells for disease and dysfunction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anastasia Yu EfimenkoDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, Lomonosov Moscow State University , Moscow, Russian Federation .
Tatiana N KocheguraDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, Lomonosov Moscow State University , Moscow, Russian Federation .
Zhanna A AkopyanDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, Lomonosov Moscow State University , Moscow, Russian Federation .
Yelena V ParfyonovaDepartment of Biochemistry and Molecular Medicine, Faculty of Medicine, Lomonosov Moscow State University , Moscow, Russian Federation . ; Laboratory of Angiogenesis, Russian Cardiology Research and Production Complex , Moscow, Russian Federation .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During recent years different types of adult stem/progenitor cells have been successfully applied for the treatment of many pathologies, including cardiovascular diseases. The regenerative potential of these cells is considered to be due to their high proliferation and differentiation capacities, paracrine activity, and immunologic privilege. However, therapeutic efficacy of the autologous stem/progenitor cells for most clinical applications remains modest, possibly because of the attenuation of their regenerative potential in aged patients with chronic diseases such as cardiovascular diseases and metabolic disorders. In this review we will discuss the risk factors affecting the therapeutic potential of adult stem/progenitor cells as well as the main approaches to mitigating them using the methods of regenerative medicine.

Identifiers

PMID26309780
PMCPMC4497652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.